A Comprehensive Review on Transdermal Drug Delivery Systems: Principles, Formulation, Evaluation, Recent Advances and Future Perspectives

A transdermal drug delivery system (TDDS) is a specific device to deliver drugs through the skin into the blood stream, providing controlled and sustained therapeutic effects.

Allow the drug to penetrate the skin and reach the systemic circulation to produce the desired therapeutic effect. The quest for novel drug delivery systems has resulted in great progress in pharmaceutical sciences, including the field of Transdermal Drug Delivery Systems (TDDS). These systems, often referred to as "patches", are carefully formulated dosage forms designed to deliver a therapeutically effective amount of a drug through a patient's skin. The evolution of drug delivery systems has been driven by the need to optimize drug therapy. Conventional oral drug administration, while convenient, is often associated with limitations such as erratic absorption, hepatic first-pass metabolism, and the potential for gastrointestinal irritation. Such limitations can diminish drug bioavailability, necessitate frequent dosing regimens, and ultimately reduce patient compliance. In contrast, TDDS offer a potential alternative to the traditional delivery systems by providing sustained release of drug, avoiding first pass metabolism and reducing the fluctuations in plasma drug concentrations. The development of TDDS is a paradigm shift in drug delivery and has the potential to improve the therapeutic outcome of a wide variety of drugs. This review will discuss the basic principles of TDDS, advantages, limitations, mechanisms of drug permeation, critical components and recent advances in this dynamic field.

1. 1.  History of Transdermal Patches

Early Topical Treatment Applications Topical treatments have been used for medicinal purposes for thousands of years, across cultures and civilizations. These early uses established the foundation for modern transdermal medication delivery systems. Here are some significant elements about the history and evolution of topical therapies.

1.1.1 Ancient Civilizations and Herbal Remedies

• Egyptians: The ancient Egyptians made considerable use of topical treatments for therapeutic purposes. They used a range of plant-based ointments and poultices to heal wounds, skin problems, and infections. Their compositions frequently included honey, animal fats, and plant extracts (Flynn, 1996; Zugerman & Fowler, 1996).
• Greeks and Romans: Topical therapies were an important feature of ancient Greek and Roman medicine. Physicians such as Hippocrates and Galen documented the use of natural salves and plasters, such as olive oil, beeswax, and therapeutic plants. These treatments were utilized to relieve pain, reduce inflammation, and enhance wound healing (Chien, 1992; Jasti and Bunge, 2002).
• Topical medicines have been used for therapeutic purposes in Traditional Chinese Medicine (TCM) for many years. Herbal-based balms, oils, and poultices were used to alleviate muscle discomfort, arthritis, and skin problems. Acupuncture and moxibustion can enhance topical therapy (Prausnitz & Langer, 2008).^[1]

1.1.2 Medieval and Renaissance Periods

• During Medieval Europe, monastic communities and physicians conserved and extended their knowledge of herbal medicine and topical therapies. Remedies frequently included frankincense, myrrh, and plants. These remedies were utilized for various diseases, including skin infections and joint pain (Cevc, 2004).
• During the Renaissance, there was a renewed interest in studying natural remedies and medicine. Advancements in botanical science and pharmacology have resulted in more sophisticated topical therapies. Alchemists and apothecaries experimented with different formulas to improve the effectiveness of their preparations (Barry, 2001).

1.1.3 18th and 19th Centuries: Foundations of Modern Pharmacology

• The 18th and 19th centuries saw substantial advancements in the science of pharmacology. Drug absorption and skin permeability become well understood. Topical therapies have been studied by physicians and scientists for their potential systemic effects (Mitragotri & Langer, 2004).
• New Ingredients: The discovery of iodine and Sulphur increased the number of topical remedies accessible. According to Benson (2005), these chemicals were utilized to treat skin problems and infections.^[1]

1.1.4 20th Century: Transition to Modern Transdermal Patches          

• In the early 1900s, improved topical formulations such as creams, gels, and lotions emerged. These products aim to improve the absorption of active substances through the skin (Wiedersberg & Guy, 2014).
• In the mid to late twentieth century, transdermal medication delivery gained popularity. In 1979, the FDA approved the first transdermal patch to treat motion sickness with scopolamine. This constituted a key milestone in the history of topical therapies, leading to the development of contemporary transdermal patches (Prausnitz & Langer, 2008).^[1]
  2. Structure and Physiology of Skin

 

 

Figure 1: structure and physiology of skin

 

 

Figure 2: Drug permeation pathways in the skin (stratum corneum shown): (a) the ap pendageal route, (b) the transcellular route, and (c) the tortuous extracellular route. The transcellular and intercellular routes constitute the trans epidermal pathway.

1. 4. Factors affecting permeation and penetration

Transdermal absorption (TA) is influenced by a complicated set of variables that work together. Clinical reaction to TDDS application is a step-by-step process:

1. Drug Release from Formulation.
2. The penetration and infiltration of the skin.
3. Activation of the pharmacological response Factors impacting TA include skin biology, medication and vehicle chemistry, and dosage conditions.

1.4.1 Biological factor

Biological factors such as skin thickness, regional location, age, blood flow rate, and skin condition can all impact penetration and permeation.^[5] Skin permeability can be affected by physical, chemical, and pathological factors, including UV, infrared, and ionizing radiation.^[6,7] Mixtures of polar and non-polar solvents can delipidize skin, Create artificial shunts in the skin.^[8] Using certain solvents can significantly reduce the skin's barrier function. The significance of drug metabolism in the skin has been overlooked in previous research. Recent results indicate that studying skin metabolism is important for designing and activating prodrugs.^[9,10]

1.4.2 Physicochemical factors

Percutaneous absorption is influenced by the physicochemical properties of both the medication and the medium, in addition to the stratum comeum structure.^[11,12] The             things to consider are the drug's molecular characteristics and the vehicle. The TA of a            drug depends on its molecular weight, size, structure, partition coefficient, pH, and    concentration on the skin's surface,^[13,14] as well as the nature and effect of the vehicle    and other chemicals that may promote sorption. The impact of individual parameters on penetration and permeation is a crucial aspect of dermal/TDDS.^[15,16]

1. 5.  Advantages and Limitations of TDDS

1.5.1Advantages

• Steer clear of first-pass metabolism.
• By avoiding the hepatic first-pass impact, TDDS can greatly improve some medications' bioavailability.
• Enhanced Adherence to Care.
• TDDS is especially well suited for long-term treatment due to its non-invasive, painless application and less frequent doses.
• Sustained and Regulated Release.
• TDDS keeps plasma drug concentrations constant and lowers the frequency of doses by enabling the controlled release of medications over a prolonged period of time.
• Decreased Gastrointestinal Adverse Reactions.
• TDDS reduces gastric discomfort and breakdown by digestive enzymes because the medication is not consumed.
• Simple Termination of Treatment.
• If side effects arise, drug administration can be swiftly stopped by taking off the patch.
• Self-management and ease of use.^[17]

            1.5.2 Limitations

• Characteristics of the Stratum Corneum Barrier.
• Most medications cannot pass through the skin's outermost layer, particularly big, hydrophilic, or ionic compounds.
• Only a Few Appropriate Drugs.
•  Transdermal administration is only appropriate for medications that possess certain qualities, such as low molecular weight, lipophilicity, and efficacy.
•  Allergy Reactions and Skin Irritation.
•  In certain cases, prolonged patch application or enhancement use may result in irritation, sensitization, or contact dermatitis.
•  Unpredictable Drug Absorption.
•  Skin condition, moisture, temperature, application place, and individual differences can all affect absorption.
•  Dosage Dumping Risk.
•  Uncontrolled drug release and toxicity may result from patch damage or external factors (such as heat).
•  Dose capacity is limited.^[17]

1. Ideal Properties of Drugs for Transdermal Delivery

• Non-allergic, non-irritating, and non-toxic. Pharmacologically inert.
• It works well at low concentrations.
• Quick action with a predictable and reversible outcome.
• Aesthetically pleasing.
• Compatible with the medication and other ingredients in the formulation.

2. Components of Transdermal Patches

3.1 Drug (API)

The selection of APIs for transdermal delivery is critical. Ideal candidates are drugs with:

• Low molecular weight
• Adequate lipophilicity
• High potency, as only small amounts can permeate the skin

• Diclofenac
• Cefixime
• Buprenorphine^[18]

3.2 Polymer Matrix

The polymer matrix is an important component of transdermal patches because it contains the medicine and regulates its release. There are numerous polymers that can be employed, each with its own set of features to meet various drug delivery requirements. Examples of polymers used in transdermal patches are:

• Polyvinyl Alcohol (PVA) is known for its film-forming characteristics and biocompatibility. 
• Ethyl Cellulose (EC) is a suitable ingredient for sustained release formulations due to its regulated release and water-insoluble properties.
• Hydroxypropyl Methylcellulose (HPMC) has excellent film-forming characteristics and controlled drug release.
• Polyvinylpyrrolidone (PVP) is known for its strong adherence and ability to create clear, flexible films.
• Polyethylene Glycol (PEG), known for its flexibility and hydrophilicity, is commonly utilized to improve medication solubility and release rates.[18]

3.3 Permeation Enhancers

Permeation enhancers are chemicals that increase skin permeability, hence improving medication absorption. Common enhancers are:

• Alcohols (such as ethanol)
• Fatty acids (such as oleic acid).
• Surfactants, such as sodium lauryl sulphate (Cevc, 2004).^[18]

3.4 Adhesives

Adhesives are crucial for ensuring the patch adheres to the skin. Commonly used adhesives include:

• Acrylate-based adhesives
• Silicone-based adhesives
• Polyisobutylene-based adhesives ^[18]
  5.  Backing Layer

The backing layer provides structural support while also protecting the patch from environmental elements. It is often composed of:

• polyester films
• Aluminium foil laminates.^[18]
  6.  Release Liners

Release liners protect the adhesive layer and are removed before patch application. They are usually composed of:

• Silicone-coated paper
• Polyethylene-coated paper^[18]

3. Methods of Preparation of Transdermal PATCHES ^[19]

• Asymmetric TPX membrane method
• Circular Teflon mould method
• Mercury substrate method
• By using “IPM membranes” method
• By using “EVAC membranes” method.

4.1 Asymmetric TPX Membrane Method:

The dry or wet inversion procedure is used to prepare them. In order to create a polymer solution, TPX is dissolved at 60°C in a mixture of solvent (cyclohexane) and non-solvent additives. After a full day at 40°C, the polymer solution is cast onto a glass             plate. The glass plate must then be submerged right away in a coagulation bath (temperature maintained at 25°C) after the casting film has been evaporated for 30 seconds at 50°C. The membrane can be taken out after 10 minutes of immersion and allowed to air dry for 12 hours at 50°C in a circulation oven.

4.2 Circular Teflon Mould Method:

Baker and Heller discovered it in 1989. Polymeric solutions in varying amounts are utilized as organic solvents. Then the solution is separated into two halves. Dissolve a calculated amount of medication in one part and varied concentrations of enhancers in another. Mix the two parts together. A plasticizer (such as Di-Nbutylphthalate) is added to the drug polymer solution. Stir the mixture for 12 hours before pouring into a round Teflon mould. To manage solvent vaporization in a laminar flow hood model, position the moulds on a level surface and cover them with an inverted funnel. An airspeed of 0.5 m/s. The solvent is allowed to evaporate for 24 hours. After drying, the film should be stored for 24 hours at 25±0.5°C in a silica gel desiccator before evaluation to prevent aging effects.

4.3 Mercury Substrate Method:

In this process, the medication and plasticizer are dissolved in polymeric solution. Stir for 10-15 minutes to create a homogeneous dispersion. Pour into a leveled mercury surface and cover with an inverted funnel to control solvent evaporation.

4.4 By Using “IPM Membranes” Method:

The medication is distributed in a mixture of water and Carbomer 940 polymer (containing propylene glycol) and swirled for 12 hours using a magnetic stirrer. To neutralize and make the dispersion thick, add triethanolamine. To generate solution gel with low drug solubility in aqueous solution, use Buffer pH 7.4. The produced gel will be integrated into the IPM membrane.

4.5 By Using “EVAC Membranes” Method:

TDS preparation requires a rate control membrane consisting of 1% carbopol reservoir gel, polyethelene (PE), and ethylene vinyl acetate copolymer (EVAC). If the medicine is not soluble in water, use propylene glycol for gel formation. After dissolving the drug in propylene glycol, add carbopol resin and neutralize with a 5% w/w sodium hydroxide solution. The medicine (in gel form) is deposited on a backing layer that covers the desired area. To create a leak-proof device, lay a rate-controlling membrane over the gel and seal the borders with heat.^[19]

4. EVALUATION PARAMETERS OF TRANSDERMAL PATCHES ^[20]

5.1 Pre-Formulation Study

Physicochemical parameters include the drug's solubility, partition coefficient, pH, and melting point. Polymer selection ensures optimal adhesion, medication release and mechanical quantities
5.2 Physicochemical Evaluation

Appearance: smoothness, transparency, and homogeneity. Thickness: A micrometer or Vernier caliper was used to take the measurements. Weight Variation: Ensures consistent distribution of components.

5.3 Adhesion and Mechanical Properties

Tensile strength determines mechanical strength.

5.4 Permeation Studies

Skin permeation was assessed using excised animal or human cadaver skin in Franz diffusion cells. Enhancement studies: The effect of permeation enhancers is investigated.

5.5 In-vivo Evaluation Skin irritation or sensitization:

Therapeutic efficacy is measured in clinical trials.

5.6 Stability Studies

Followed ICH requirements in accelerated conditions (temperature and humidity) to guarantee patch integrity, adhesion, and medication content stability.

5. Permeation Enhancement Techniques
   • • Physical approach
     • Chemical approach
     • Colloidal carriers

Physical approach: To open the skin's pores, physical enhancers physically engage with the skin in a variety of ways, causing harm to the skin's integrity. It was discovered that iontophoresis and permeation enhancers worked well together to deliver drugs.
Iontophoresis:

An electrode with the same charge as the drug molecules is placed on the skin, and a current of a few milliamperes (less than 0.5 mA) is applied. The electrode declines the drug molecules with the same charge through the skin to the electrode with the opposite charge, and the drug is delivered quickly. For improved outcomes, iontophoresis can be combined with chemicals, electrophoresis, or ultrasound.

SONOPHORESIS:

The medicine is delivered through the skin by breaking the lipid bilayer when sound waves with frequencies between 20 KHz and 10 MHz are applied to the skin for 15 seconds. When the medication is combined with a coupling agent, both the medication and the sound waves are transmitted through the skin. By eliminating first-pass metabolism, efflux transporters, digestive enzymes, and adverse circumstances associated with other oral administration, this method allows bioactive compounds to enter the systemic circulation directly.

CHEMICAL APPROACHES:

 Chemical permeation enhancers and iontophoresis improve the penetration of antihypertensive agents through the skin. The combination of iontophoresis with permeation enhancers was shown to be promising in delivering atenolol across the skin, with the maximum penetration attained when oleic acid was used as a chemical enhancer with iontophoresis. The in vitro flux value (when oleic acid was paired with iontophoresis) was 0.71 mg/cm2/h, indicating that a therapeutically appropriate concentration can be achieved with 1.2cm2 of skin area.^[21]

MULTIPLE OR DOUBLE EMULSION: 

Multiple emulsion systems are new technologies with promise oral administration.             Multiple emulsions, also known as emulsions of emulsions, are made up of liquid that        is miscible with and sometimes identical with the continuous phase. This is made            feasible via twofold emulsification, hence the name double emulsion. It contains both hydrophilic and lipophilic emulsifiers that are used to generate numerous emulsions.

Double emulsions aid to keep drug concentrations within the therapeutic range in lymph vessels. Drugs are transported to mesenteric lymph nodes rather than straight into the portal system because they are encapsulated by the oil phase, which has a higher             lipophilic character and so is absorbed by lymphatic channels. Furthermore, w/o/w emulsions may serve as carriers for the delivery of polypeptide/protein drugs, which require both protection from gastric fluids and delivery via lymph nodes.

SOLID LIPID NANOPARTICLES (SLNS):

It is an aqueous colloidal dispersions made of biodegradable lipids. They can be found             in emulsions, liposomes, and polymeric micro- and nanoparticles. SLNs have gained popularity due to their increased solubility and oral bioavailability through various mechanisms.^[22]

6. Characterization Techniques for Transdermal Patches

Characterization procedures are critical in evaluating the quality, performance, and             stability of transdermal patches. Here are some important characterisation techniques:

7.1 Physical Characterization:

• Patch thickness: Measured with a micrometer or thickness gauge. The same thickness promotes consistent drug release and adherence.
• Weight Uniformity: Multiple patches are weighed and averaged to ensure uniform distribution of medication and excipients.
• Visual inspection: Check for problems like cracks, delamination, or discolouration.

7.2 Mechanical Characterization:

• Tensile Strength: Tests the force needed to break the patch. The patch's mechanical integrity and flexibility are evaluated to ensure pleasant use and adherence.
• Puncture Resistance: Testing assesses the patch's resistance to sharp object penetration, replicating real-world scenarios where the patch may be penetrated accidently during application or wear.

7.2.1 Adhesive Properties:

• Adhesion Strength: Adhesion testing determines the force needed to remove the patch from the skin. It assesses adhesive characteristics and guarantees the patch stays in place during wear.
• Peel Adhesion Test: Evaluates the bond strength between the adhesive layer and backing materials. It determines how easily the patch may be removed without leaving residue or causing skin irritation.^[23]

7.2.2 Drug Release Studies:

• Franz Diffusion Cells: It replicates drug release via the skin in vivo. The patch is inserted between the donor and receptor compartments, and drug permeation through the skin is tracked over time.
• In vitro skin permeation studies: It involve mounting excised animal or human skin in diffusion cells and applying a patch to the skin's surface. The drug's permeation through the skin is assessed to evaluate its kinetics and penetration.^[24]

7.2.3 Microscopic Analysis:

• Scanning Electron Microscopy (SEM): It captures high-resolution images of the patch surface, revealing microstructure, shape, and flaws.
• Atomic Force Microscopy (AFM): It analyses surface roughness, topography, and mechanical characteristics at the nanoscale, providing valuable insights on patch structure.^[25]

7.3 Chemical Characterization:

• Fourier Transform Infrared Spectroscopy (FTIR): It detects functional groups and chemical bonds in patch components, proving the presence of polymers, plasticizers, and drugs.
• Differential Scanning Calorimetry (DSC): It analyses heat flow during physical changes in patch components, such as melting or crystallization, to determine thermal behaviour and ingredient compatibility.^[26]

7. Therapeutic Applications of Transdermal PATCHES

Transdermal patches are used for a variety of medicinal purposes

8.1 Pain Management:

Patches containing fentanyl, lidocaine, or diclofenac offer long-lasting analgesia for chronic pain and cancer patients.

8.2 Hormone Replacement Therapy:

Estradiol and testosterone patches treat menopausal symptoms and hypogonadism, respectively.   

8.3 Cardiovascular Disorder:

Medications for cardiovascular disorders include nitroglycerin patches for angina and clonidine patches for hypertension.
8.4 Central Nervous System Disorders:

Patches containing rivastigmine for Alzheimer's disease and methylphenidate for ADHD improve compliance in both geriatric and pediatric populations.

8.5 smoking cessation:

Nicotine patches can alleviate withdrawal symptoms and cravings during smoking cessation programs.  

8.6 Contraception:

Scopolamine patches can help avoid motion sickness and post-operative nausea. Transdermal devices containing estrogen and progestin offer weekly contraceptive coverage.

8. Recent Advances in Transdermal Drug Delivery

Nanotechnology has shown promise in improving topical and transdermal drug delivery, particularly for biologics. Biologics are gaining popularity in transdermal administration due to their biological barriers that limit medication absorption. Novel therapeutics for inflammatory illnesses include tralokinumab, baricitinib, and anti-IL-4R antibodies. The FDA has approved ruxolitinib cream, the first topical JAK inhibitor, to treat mild to severe atopic dermatitis that cannot be effectively managed with conventional topical medicines.^[32]

Hyaluronic acid-based solutions are becoming prominent in the pharmaceutical industry due to their high permeability and biocompatibility. Hyaluronic acid-based nanoparticles, ethosomes, and liposomal transdermal systems are utilized to treat anti-inflammatory illnesses such atopic dermatitis and psoriasis. Researchers are exploring physical penetration approaches for transdermal delivery, including sonophoresis, iontophoresis, and electroporation, in addition to microneedles. These approaches are widely regarded as effective, safe, and have a high medication bioavailability. Electroporation uses tiny electrical impulses to improve the entry of hydrophilic medicines into the stratum corneum. Sonophoresis uses ultrasonic waves at different frequencies to break the epidermal barrier and increase medication penetration. Iontophoresis uses an electric field to drive molecules into the skin, resulting in fast medication release for both charged and uncharged molecules. Low-frequency ultrasound promotes better drug penetration than high-frequency ultrasound. However, patient-specific models present hurdles in terms of cost and large-scale viability. These emerging approaches have the potential to transform transdermal drug delivery, providing patients with better treatment alternatives.^[33]

9.  Challenges and Limitations of Transdermal Patches

While transdermal patch technology has several benefits in medication administration, it also has some problems and limits that prevent general adoption and efficacy ^[34,35]. Addressing these problems is critical for moving the field forward and realizing the full potential of transdermal patch technology. This section delves into some of the primary issues and constraints found during transdermal patch development and distribution.

10.  Future Prospects of Transdermal Drug Delivery ^[36-41]

            11.1 Developing Advanced Skin Penetration Technologies:

New technologies like microneedles, iontophoresis, sonophoresis, electroporation, and thermal ablation are enhancing medication absorption through the skin barrier. These approaches can help transport big molecules like peptides, proteins, and vaccinations that were previously difficult to inject transdermally.

11.2 Integration of Nanotechnology:

Nanocarriers such as liposomes, niosomes, ethosomes, transferosomes, solid lipid nanoparticles, and nanostructured lipid carriers are thought to promote medication penetration, bioavailability, and controlled release. Transdermal systems based on nanotechnology have the potential to change chronic illness management.

11.3 Personalised medicines:

Future transdermal patches could be tailored to individual patients' needs, taking into account characteristics such as age, body weight, medical state, and genetic profile. Personalized patches can improve therapeutic success while reducing side effects.

11.4 Smart and Wearable Drug Delivery Systems:

The incorporation of sensors, microelectronics, and wireless communication technologies into transdermal patches is resulting in intelligent medication delivery systems.

These devices can monitor physiological factors and automatically alter drug release in response to patient needs.
11.5 Delivery of biopharmaceuticals:

The goal of the research is to enable transdermal administration of biologics such insulin, growth hormones, vaccines, monoclonal antibodies, and nucleic acid-based therapies. This development has the potential to eliminate the need for injections and enhance patient compliance.
11.6 Improved Treatment of Chronic Disease:

Future TDDS applications are predicted to include the management of diabetes, cardiovascular disease, neurological disorders, pain management, hormone replacement therapy, and cancer treatment via sustained and targeted medication delivery.

11.7 Improved patient compliance:

Transdermal methods provide painless administration, reduced dose frequency, and the prevention of gastrointestinal adverse effects. These benefits will continue to boost their use, especially among pediatric, geriatric, and chronic disease patients.
11.8 Combined Drug Delivery Systems:

Researchers are developing patches that can deliver many medications at once. Such methods may enhance therapy efficacy and simplify treatment regimens for complex disorders.

11.9 Sustainable and biodegradable materials:

The future of TDDS includes the development of ecologically friendly and biodegradable polymers that reduce waste and improve biocompatibility while maintaining drug delivery performance.

11.10 Expanded Vaccine Delivery:

Microneedle-based transdermal vaccination delivery methods have demonstrated substantial promise. They provide pain-free administration, greater immunological responses, and easier storage and transportation than traditional injections.

CONCLUSION

Transdermal drug delivery systems (TDDS) have emerged as a potential and successful alternative to traditional drug delivery methods, thanks to its capacity to provide regulated and sustained release of therapeutic substances through the skin. Transdermal patches are formulated by carefully selecting medicines, polymers, adhesives, plasticizers, and permeation enhancers to promote optimal drug release skin permeation. Various preparation processes and evaluation parameters are critical in ensuring that the generated patches are of high quality, safe, effective, and stable. The examination of transdermal patches using physicochemical, mechanical, and permeation tests aids in establishing their performance and therapeutic utility. Recent innovations such as microneedles, nanocarrier-based systems, iontophoresis, and smart transdermal technologies have considerably increased the scope of transdermal drug delivery, allowing for the administration of a broader range of medications with enhanced bioavailability and patient compliance. Despite problems such as restricted drug penetration, skin irritation, and formulation complications, ongoing research and technology advancements are overcoming these constraints. The increased interest in non-invasive drug delivery technologies and individualized medicine emphasizes the utility of transdermal patches in modern healthcare. As a result, transdermal patches constitute a valuable and expanding drug delivery platform with tremendous potential for future pharmaceutical development and therapeutic applications.

REFERENCES

1. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. Br J Pharmacol. 2015;172(9):2179-2209.
2. Potts RO, Guy RH. Predicting skin permeability. Pharm Res. 1992;9:663-669.
3. Moss GP, Dearden JC, Patel H, Cronin MTD. Quantitative structure-permeability relationships (QSPRs) for percutaneous absorption. Toxicol In Vitro. 2002;16:299-317.
4. Magnusson BM, Pugh WJ, Roberts MS. Simple rules defining the potential of compounds for transdermal delivery or toxicity. Pharm Res. 2004;21:1047-1054.
5. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of cortisol in man. J Invest Dermatol. 1967;48:181-183.
6. Elias PM. Lipids and the epidermal permeability barrier. Arch Dermatol Res. 1981;270:95-117.
7. Behl CR, Bellantone NH, Flynn GL. Influence of age on percutaneous absorption of drug substances. In: Bronaugh RL, Maibach HI, editors. Percutaneous Absorption. New York: Marcel Dekker; 1985. p. 183-212.
8. Ritschel WA. Applied Biopharmaceutics. Cincinnati (OH): University of Cincinnati; 1971. p. 1229-1244.
9. Menczel E. Delipidization and percutaneous absorption. In: Bronaugh RL, Maibach HI, editors. Percutaneous Absorption. New York: Marcel Dekker; 1985. p. 133-139.
10. Wiedmann TS. Influence of hydration on epidermal tissue. J Pharm Sci. 1989;77:1037-1041.
11. Xu P, Chien YW. Enhanced skin permeability for transdermal drug delivery: physiopathological and physicochemical considerations. Crit Rev Ther Drug Carrier Syst. 1991;8:211-236.
12. Higuchi T. Pro-drugs, molecular structure and percutaneous delivery. In: Roche EB, editor. Design of Biopharmaceutical Properties Through Prodrugs and Analogs. Washington (DC): American Pharmaceutical Association; 1977. p. 409-421.
13. Bucks DAW. Skin structure and metabolism: relevance to the design of cutaneous therapeutics. Pharm Res. 1984;1:148-153.
14. Guy RH, Hadgraft J, Bucks DAW. Transdermal drug delivery and cutaneous metabolism. Xenobiotica. 1987;17:325-343.
15. Pannatier PJ, Testa B, Etter JC. The skin as a drug metabolizing organ. Drug Metab Rev. 1978;8:319-329.
16. Abraham MH, Chadha HS, Mitchell RC. The factors that influence skin penetration of solutes. J Pharm Pharmacol. 1995;47:8-16.
17. Dhavan P, Chavan O, Gaikwad S. Transdermal drug delivery systems: advances, challenges, and future perspectives. Int J Pharm Sci. 2025;3(4):3064-3074.
18. Fatima A, Apte SS. Formulation and development of transdermal patches. GSC Biol Pharm Sci. 2022;19(1):346-352.
19. Berner B, John VA. Pharmacokinetic characterization of transdermal delivery systems. Clin Pharmacokinet. 1994;26(2):121-134.
20. Patel RP, Patel G, Baria A. Formulation and evaluation of transdermal patch of aceclofenac. Int J Drug Deliv. 2009;1(1):41-51.
21. Gökçe EH, Kaynak MS, Yurdasiper A, Üstündağ-Okur N, Şahin S. Comparison of intestinal permeability of nebivolol hydrochloride loaded solid lipid nanoparticles with commercial nebivolol tablet. Marmara Pharm J. 2018.
22. Chaolong Qin, Yenju Chu, Wanshan Feng, et al. Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach, 2020, National library of medicine
23. Williams, A. C., & Barry, B. W. (2012). Penetration enhancers. Advanced drug delivery reviews, 64, 128–137.
24. Roberts, M. S., & Cross, S. E. (1999). Permeability of human skin: a review. British Journal of Dermatology, 146(6), 1017–1031.
25. Kolli, C. S., & Banga, A. K. (2008). Characterization of solid maltose microneedles and their use for transdermal delivery. Pharmaceutical research, 25(1), 104–113
26. Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. European journal of pharmaceutical sciences, 14(2), 101–114
27. D NV, Shrestha N, Sharma J. Transdermal drug delivery system: an overview. Int J Res Pharm Sci. 2012;3(2):234–41.
28. Jayaprakash S, Ramkanth S, Anitha P, Alagusundaram M, Saleem MT, Chetty MC. Design and evaluation of monolithic drug-in-adhesive transdermal patches of meloxicam. Malays J Pharm Sci. 2010;8(2):25–43.
29. Patel AV, Shah BN. Transdermal drug delivery system: a review. Int J Pharm Sci. 2018;9(1):378–90.
30. Sharma K, Mittal A, Agrahari P. Skin permeation of candesartan cilexetil from transdermal patch containing aloe vera gel as penetration enhancer. Asian J Pharm. 2016;10(2):124–31.
31. John L, Kumar A. Comparison of amlodipine transdermal patches using hydroxypropyl methylcellulose and chitosan. Asian J Pharm Clin Res. 2014;7(1):86-90.
32. Kim YC, Ludovice PJ, Prausnitz MR. Transdermal delivery enhanced by magainin pore-forming peptide. J Control Release. 2007;118(1):1-6.
33. Böttiger LE, Svedman P, Gustavsson G, Norman C. Patch testing with corticosteroids: multicentre study of a corticosteroid series. Br J Dermatol. 1986;115(5):551-558.
34. Escobar-Chávez JJ, Díaz-Torres R, Rodríguez-Cruz IM, Domínguez-Delgado CL, Morales RS, Ángeles-Anguiano E, Melgoza-Contreras LM. Nanocarriers for transdermal drug delivery. Res Rep Transdermal Drug Deliv. 2012;1:3-17.
35. Saroha K, Yadav B, Sharma B. Transdermal patch: a discrete dosage form. Int J Curr Pharm Res. 2011;3(3):98-108.
36. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268.
37. Ita K. Transdermal delivery of drugs with microneedles: potential and challenges. Pharmaceutics. 2015;7(3):90-105.
38. Alexander A, Dwivedi S, Giri TK, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 2012;164(1):26-40.
39. Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol. 2012;64(1):11-29.
40. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175-187.
41. Ahmed TA. Transdermal drug delivery systems: current technologies and future prospects. Am J Drug Discov Dev. 2015;5(3):95-112.